ER ligands ameliorate fatty liver through a non-classical ER / LXR pathway

Song-iee Han (shan@tara.tsukuba.ac.jp), Yoko Komatsu (s0310868_yoko@yahoo.co.jp), Akiko Murayama (akikomrym@agbi.tsukuba.ac.jp), Knut R. Steffensen (Knut.Steffensen@ki.se), Yoshimi Nakagawa (yosshy@md.tsukuba.ac.jp), Yuka Nakajima (nakajima@tara.tsukuba.ac.jp), Michiko Suzuki (s0910720@u.tsukuba.ac.jp), Shohei Oie (s_ooie@tara.tsukuba.ac.jp), Paolo Parini (Paolo.Parini@ki.se), Lise-Lotte Vedin (Lise-Lotte.Vedin@ki.se), Hiroyuki Kishimoto (h-kishimoto@tara.tsukuba.ac.jp), Hitoshi Shimano (hshimano@md.tsukuba.ac.jp), Jan-Åke Gustafsson (jgustafs@Central.UH.EDU), and Junn Yanagisawa (junny@agbi.tsukuba.ac.jp)